Trials / Completed
CompletedNCT02700685
Effect of Pycnogenol® on ADHD
Effect of a Polyphenol-rich Plant Extract on Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Double Blind, Placebo and Active Product Controlled Multicenter Trial.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Nina Hermans · Academic / Other
- Sex
- All
- Age
- 6 Years – 12 Years
- Healthy volunteers
- Not accepted
Summary
This double blind, randomised controlled trial examines the effect of a commercially available nutritional supplement on behaviour of ADHD patients, as well as on their physical and psychiatric co-morbidities, and level of oxidative stress and immune activity, as compared to placebo and standard pharmaceutical treatment for ADHD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Pycnogenol | Dietary supplement, standardised extract of French maritime Pine bark. This group receives a nutritional supplement for a period of 10 weeks. |
| DRUG | Methylphenidate | Standard pharmaceutical treatment for ADHD, slow release. |
| OTHER | Placebo | Placebo treatment (identical capsules containing excipients only) |
Timeline
- Start date
- 2017-09-01
- Primary completion
- 2020-11-20
- Completion
- 2020-11-20
- First posted
- 2016-03-07
- Last updated
- 2021-04-28
Locations
3 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT02700685. Inclusion in this directory is not an endorsement.